Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 ug] and 10 ug [2 Actuations of 5 ug]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The primary objective of this study is to assess the long-term efficacy and safety of once daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat® inhaler, in patients with COPD.


Options:
A: Arm Label: Tiotropium + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium bromide, Drug: Placebo Salmeterol | Arm Label: Salmeterol + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol, Drug: Placebo Tiotropium | Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Salmeterol + Placebo | Intervention Type: DRUG; Name: Placebo Salmeterol; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Placebo Tiotropium; Assigned to Arm(s): Salmeterol + Placebo
B: Arm Label: Olodaterol (BI 1744) Low; Type: EXPERIMENTAL; Interventions: Drug: Olodaterol (BI 1744) | Arm Label: Olodaterol (BI 1744) High; Type: EXPERIMENTAL; Interventions: Drug: Olodaterol (BI 1744) | Arm Label: Formoterol 12mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olodaterol (BI 1744); Assigned to Arm(s): Olodaterol (BI 1744) Low | Intervention Type: DRUG; Name: Olodaterol (BI 1744); Assigned to Arm(s): Olodaterol (BI 1744) High | Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): Formoterol 12mcg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol Fumarate | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): 2
D: Arm Label: FF MDI (PT005); Type: EXPERIMENTAL; Interventions: Drug: FF MDI (PT005) | Arm Label: GP MDI (PT001); Type: EXPERIMENTAL; Interventions: Drug: GP MDI (PT001) | Arm Label: GFF MDI (PT003); Type: EXPERIMENTAL; Interventions: Drug: GFF MDI (PT003) | Arm Label: Placebo MDI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GFF MDI (PT003); Assigned to Arm(s): GFF MDI (PT003) | Intervention Type: DRUG; Name: GP MDI (PT001); Assigned to Arm(s): GP MDI (PT001) | Intervention Type: DRUG; Name: FF MDI (PT005); Assigned to Arm(s): FF MDI (PT005) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo MDI

Answer: B